- Home
- NBH vs GALT Comparison
NBH vs GALT Comparison
Compare NBH & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.04
Company Overview
Basic Information| Metric | NBH | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.2M | 297.0M |
| IPO Year | 2002 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NBH | GALT |
|---|---|---|
| Price | $10.26 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 73.9K | ★ 332.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $2.03 |
| 52 Week High | $10.72 | $7.13 |
Technical Indicators
Market Signals| Indicator | NBH | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 59.90 |
| Support Level | $10.13 | $2.74 |
| Resistance Level | $10.30 | $4.35 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 54.17 | 72.03 |
Price Performance
Historical Comparison NBH
GALT
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.